YMTX Yumanity Therapeutics Inc

Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference.

The presentation will be available on-demand via the conference portal and through the Company's website at yumanity.com/events beginning January 11, 2021 starting at 6:00am EST.

About Yumanity Therapeutics

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease.

For more information, please visit .

Contacts

Investors:

Burns McClellan, Inc.

John Grimaldi



(212) 213-0006

Media:

Burns McClellan, Inc.

Ryo Imai / Robert Flamm, Ph.D.

/

(212) 213-0006

 



EN
06/01/2021

Underlying

YMTXYumanity Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Yumanity Therapeutics Inc

 PRESS RELEASE
Free
YMTX Yumanity Therap...

Yumanity Therapeutics Declares Special Dividend In Connection with Pro...

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV (“...

December 5, 2022 1 EN
 PRESS RELEASE
Free
YMTX Yumanity Therap...

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and...

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the “Registration Statement”) wi...

November 14, 2022 1 EN
 PRESS RELEASE
Free
YMTX Yumanity Therap...

Yumanity Therapeutics Announces Effectiveness of Registration Statemen...

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc. Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) today announced that the registration statement on Form S-4 (the “Registration Statement”), relating to the previously announced asset sale to Janssen Pharmaceutica NV (“Janssen”) and merger with Kineta, Inc. (“Kineta”...

November 10, 2022 1 EN
 PRESS RELEASE
Free
YMTX Yumanity Therap...

Yumanity Therapeutics Announces Filing of Registration Statement on Fo...

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”). The Registration Statement...

August 29, 2022 1 EN
 PRESS RELEASE
Free
YMTX Yumanity Therap...

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results an...

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company’s recent corporate developments. Recent Corporate Developments In June 2022, the Company announced...

August 4, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch